GlassScriptPhysician profile
Samer I Renno
NPI 1588758312
$41,380.45
in general payments reported to CMS, 2019-2025
31 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $704 · 2021: $1,757 · 2022: $5,018 · 2023: $1,643 · 2024: $284 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,388 · Food and Beverage: $1,243 · Education: $71.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,387.50 |
| Food and Beverage | $1,242.54 |
| Education | $71.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14,517.07 | 2019-2024 | Imjudo, Enhertu, Imfinzi |
| Amgen INC. | $7,044.73 | 2019 | |
| Seagen INC. | $6,259.48 | 2019-2022 | |
| Abbvie INC. | $4,749.02 | 2019-2025 | |
| Tesaro, INC. | $4,345.74 | 2019 | |
| Janssen Biotech, INC. | $1,353.84 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $1,061.04 | 2022-2025 | Enhertu, Vanflyta |
| Mckesson Specialty Care Distribution, LLC | $670.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $231.53 | 2019-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $137.75 | 2019-2023 | Imbruvica |
| Iovance Biotherapeutics, INC. | $123.09 | 2025 | Amtagvi |
| Merck Sharp & Dohme LLC | $99.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $82.11 | 2019-2025 | |
| Incyte Corporation | $82.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.42 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $70.71 | 2023-2025 | Vyloy, Xospata |
| Genentech USA, INC. | $65.93 | 2023-2025 | Lunsumio, Columvi, Polivy |
| Acrotech Biopharma INC. | $65.73 | 2021 | |
| Pharmaessentia USA Corporation | $62.07 | 2023-2025 | Besremi |
| Pfizer INC. | $46.36 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $35.00 | 2024-2025 | |
| Beone Medicines USA, INC. | $34.35 | 2025 | Tevimbra |
| Octapharma USA, INC. | $25.21 | 2025 | Octagam Immune Globulin (Human) |
| Geron Corporation | $21.60 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $21.19 | 2025 | Koselugo |
| Lilly USA, LLC | $20.77 | 2024 | Jaypirca, Verzenio |
| Adc Therapeutics America, INC. | $20.34 | 2025 | |
| Glaxosmithkline, LLC. | $17.60 | 2025 | Blenrep |
| Pharmacosmos Therapeutics INC. | $15.97 | 2023 | Monoferric |
| Celgene Corporation | $15.46 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Renno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.